The FDA approved the use of Actos (pioglitazone) for Type 2 Diabetes in the U. S. A one-year, randomized, double-blind study compared pioglitazone and the oral sulfonylureas (sulfa drugs) to treat Type 2 diabetes.
The study compared the efficacy of pioglitazone (30 mg once daily) and pioglitazone (60 mg daily) with placebo. After 12 weeks of treatment with pioglitazone, a composite of pioglitazone alone (pioglitazone and placebo) and pioglitazone plus sulphonylurea (pioglitazone plus sulphonylurea) was compared. At baseline, the patients were significantly more likely to develop type 2 diabetes in the pioglitazone plus sulphonylurea group. The pioglitazone plus sulphonylurea group had a higher rate of diabetes with a greater prevalence of diabetic complications and a higher incidence of other comorbidities.
In the pioglitazone group, the patients had fewer complications in the first year and in the pioglitazone plus sulphonylurea group in the first year, compared with the placebo group.
In the pioglitazone plus sulphonylurea group, the patients had fewer complications and no adverse events compared with the pioglitazone plus sulphonylurea group.
There were no significant differences between the two groups in the rate of diabetic complications, or in the rate of diabetes with at least one comorbidity, other than diabetes.
The pioglitazone and pioglitazone plus sulphonylurea groups were well tolerated, with a higher rate of adverse events in the pioglitazone plus sulphonylurea group.
Pioglitazone and pioglitazone plus sulphonylurea had similar efficacy in lowering blood glucose. A higher dose of pioglitazone and a lower dose of pioglitazone plus sulphonylurea were required to achieve a significant effect on blood glucose levels.
Overall, the two pioglitazone groups had similar rates of diabetes with regard to glycemic control and other comorbidities.
At 12 weeks, pioglitazone patients had a mean change from baseline of -13.4 mmol/h to -22.6 mmol/h; pioglitazone plus sulphonylurea patients had a mean change from baseline of -17.7 mmol/h to -24.2 mmol/h; pioglitazone plus sulphonylurea plus sulphonylurea patients had a mean change from baseline of -2.3 mmol/h to -1.3 mmol/h, and pioglitazone plus sulphonylurea plus sulphonylurea plus sulphonylurea plus sulphonylurea patients had a mean change from baseline of -6.2 mmol/h to -7.9 mmol/h.
The mean change in HbA1c in the pioglitazone plus sulphonylurea group was -7.3 mm/h at 12 weeks, and -4.3 mm/h at 12 weeks.
At 12 weeks, pioglitazone patients had a mean change from baseline of -0.8% to -0.3% at 12 weeks, and -0.4% to -0.3% at 12 weeks.
The difference in HbA1c changes from baseline at 12 weeks in pioglitazone and pioglitazone plus sulphonylurea patients was -2.1% (P = 0.039) and -1.9% (P = 0.029), respectively.
A higher incidence of gastrointestinal adverse events, including dyspepsia and nausea, was also observed in pioglitazone patients compared with pioglitazone plus sulphonylurea patients (2.2% vs 1.9%, P = 0.038 and 2.8% vs 3.2% vs 2.5%, P = 0.037).
Pioglitazone patients were also more likely to develop diabetes in the pioglitazone plus sulphonylurea group at 12 weeks (P = 0.003) and at Week 12 (P = 0.039), compared with pioglitazone plus sulphonylurea patients (P = 0.036 and P = 0.042), and pioglitazone plus sulphonylurea patients (P = 0.
Actos is used to treat type 2 diabetes. It is also used to treat type 1 diabetes (high blood sugar).
Read this before you start using Actos, the medicine used to treat type 2 diabetes. If you are on this medicine, your doctor may tell you to stop using it.
Actos works by lowering your body's own production of glucose. This will keep your body from producing more glucose. Actos works by preventing your body from getting into the body's metabolic rate. Actos works by blocking the action of an enzyme called glucose-6-phosphate dehydrogenase, which is responsible for converting glucose into glucose-6-phosphate. This causes your body to use glucose more effectively.
Take Actos exactly as prescribed by your doctor.
Take Actos with or without food, as it is most effective when taken with a low-fat meal.
The dosage of Actos may vary depending on your individual health. For example, if you are on insulin (or your body will respond to insulin more quickly), your doctor may start you at a lower dose of Actos. However, your doctor may gradually increase your dose in the days that you take Actos.
If you miss a dose of Actos, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
You should not use more than the recommended dose in a 24-hour period. If you have diabetes or if you have any other symptoms of this disease, contact your doctor.
Do not take more Actos than prescribed by your doctor.
You should continue your treatment for a period of 24 hours after your dosage has been adjusted.
Read the information on the Actos website (including all medicines that you buy from our pharmacy and any other information that you may read on our website).
If you are taking another medicine, you may need to change the dose of the other medicine. For example, if you have diabetes, taking a lower dose of Actos may increase your chance of developing diabetes later. You should not take more Actos than the recommended dose of your doctor’s advice.
Actos is a diabetes medicine that may help slow down or even reverse the progression of type 2 diabetes.
Actos is a prescription medicine that is sometimes prescribed for people with a type of diabetes called.
The medicine is sometimes called.
Actos is usually prescribed to people who have a type of kidney disease. Actos may also be prescribed for people with and or kidney disease.
Actos may also be prescribed for people with and kidney disease.
A prescription of Actos is an ongoing treatment.
It’s important to talk with your healthcare provider about your medical history and any other medications you take. They can determine if Actos is appropriate for you.
A side effect of Actos is to stop taking the medicine. Actos is generally not known to have any of the common side effects of the medicine.
The most common side effects of Actos are listed below.
The most common side effects of Actos include the following.
1. Weight gain (obesity)
A person may gain weight when taking Actos.
2. Headache
A person may experience the following adverse effects after taking Actos:
3. Back pain
4. Muscle pain
5. Fatigue
6.
7.
8. Muscle weakness
9. Dizziness
10. Flushing (redness)
11. Fever
12. Rash
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Preliminary Study:Study of a novel lactose-enriched lactase-free, lactose-enriched (L-E)
Deglanserin Study Group:Study of a novel lactose-enriched, lactose-enriched, L-E lactose-enriched, lactose-enriched lactase-free, lactose-enriched, L-E lactose-enriched, lactose-enriched, L-E lactose-enriched, lactose-enriched, L-E lactose-enriched, lactose-enriched, lactose-enriched, L-E lactose-enriched, L-E lactose-enriched, lactose-enriched, L-E lactose-enriched, L-E lactose-enriched, lactose-enriched, lactose-enriched, L-E lactose-enriched, and L-E lactose-enrichedClinicalstudies with patients and/or caregivers of the L-E-enriched (L-E) in the L-E-enriched studySafety and Side Effects: Safety and efficacy of the new lactose-enriched, lactose-enriched, lactose-enriched, L-E, lactose-enriched, L-E lactose-enriched, lactose-enriched, lactose-enriched, lactose-enriched, L-E lactose-enriched, lactose-enriched, and L-E lactose-enrichedStudy Design:
Study design:A randomized, double-blind, parallel group, placebo-controlled, parallel-group, double-blind, multicenter study ofL-Ein healthy adult women. Both groups receivedin doses of 2.5 to 5 mg/day and 10 to 15 mg/day for 2 to 6 months. After the first and second months of the study, the mean age of the patients was 36.9 and 40.5 years in the L-E group and 30.7 and 44.7 years in the placebo group, respectively. The mean number of children was 1.5, 1.4 and 1.0 in the L-E group, respectively, and 1.4 and 1.2 in the placebo group, respectively. The incidence of vomiting and diarrhea was significantly lower in the L-E group in the first month compared with the placebo group in the second month. No serious adverse events were reported in the L-E-treated patients. The adverse events were mostly gastrointestinal and, to a lesser extent, cardiovascular. The mean change from baseline was -0.5 mg/day in the L-E group (p = 0.03), -0.5 mg/day in the placebo group (p = 0.02), -0.5 mg/day in the L-E group (p = 0.03), and -0.5 mg/day in the placebo group (p = 0.02) compared with the placebo-treated patients. The average change from baseline in weight for the L-E group was -0.4 kg/day (p = 0.02). There were no differences in the incidence of gastrointestinal adverse events between the L-E-treated and placebo group. The most common adverse events were gastrointestinal hemorrhage, diarrhea, and flatulence, and these adverse events were mostly gastrointestinal, including: constipation, diarrhea, and vomiting. The mean change from baseline in weight for the L-E group was -0.5 mg/day (p = 0.03), -0.5 mg/day (p = 0.03), -0.5 mg/day (p = 0.02), and -0.5 mg/day (p = 0.03) compared with the placebo-treated patients. There were no serious adverse events in the L-E group. The mean change from baseline in weight for the placebo group was -0.5 mg/day (p = 0.02), -0.5 mg/day (p = 0.02), and -0.5 mg/day (p = 0.02) compared with the placebo-treated patients. There were no significant differences in the incidence of serious adverse events between the placebo group (p = 0.96) and the L-E group (p = 0.42) in the placebo group.
Generic name:Pioglitazone - oral
Pronunciation(act-toe-lti-zole)
Brand name(s)Actos, Pioglitazone
Pioglitazone is used to treat a variety of different conditions (such as to lower blood pressure, to treat high blood pressure). It works by lowering the levels of certain chemicals in the body (such as triglycerides and cholesterol) that cause blood pressure to improve. This lowers the chance of heart attacks, andPioglitazone is used to treat other conditions (such as high blood pressure). It is used to treat the symptoms of benign prostatic hyperplasia (BPH), to stop blood clots from returning, and to treat the symptoms of an enlarged prostate.
Pioglitazone is also used to treat other conditions caused by a deficiency of an enzyme called type 2 diabetes-2 (also called "diabetic thyroid hormones"). This enzyme can cause prostate enlargement and can make you more likely to develop BPH.
Pioglitazone is not a diabetes medicine. It will not treat the conditions you have.
Read the Patient Information Leaflet if available from your pharmacist before you start taking Pioglitazone and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth, with or without food, usually once daily, every 12 hours. The dosage is based on your medical condition and response to treatment.
If you are taking the missed dose, take it as soon as you remember. If you are taking the dose that you remember about and forget any dates, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for the missed one.
If you are taking the dose that your doctor has prescribed for you, it is important to make sure that it is clearly stated on the medicine label. For example, the prescription label should say that the medicine is used to treat high blood pressure and not used to treat BPH. If you are taking the prescription, it is important to choose a strength that is bioequivalent to the drug's active ingredient. This means that your doctor will determine the strength of the strength for you depending on your medical condition and response to treatment.
Pioglitazone may not work if you are taking other medicines or have other serious side effects. Ask your doctor about other medicines you are taking that may interact with Pioglitazone.
Tell your doctor about all the medicines you are currently taking. Pioglitazone may also interact with other drugs (such as some anti-epileptic medicines and diuretics) and alcohol. These drugs may increase your chance of developing BPH if you take them together.
Your doctor will determine how you should take Pioglitazone, and you may need to take Pioglitazone with or without food. If you take a medicine with a high fat content, it may slow down how long it stays in your body. Also, low fat foods may make taking Pioglitazone more effective. Ask your doctor about other ways you can lower your fat content.
A small amount of fat can increase your risk of developing BPH. This risk is greater if you have BPH before you start using Pioglitazone and have high blood pressure before you start using Pioglitazone. Talk with your doctor if you have any questions or concerns about starting or using Pioglitazone.
You may need to take Pioglitazone at least 6 months before any kind of surgery or other treatment.
Tell your doctor if your condition does not get better or if it gets worse (for example, your blood pressure is getting worse or gets worse).
Take Pioglitazone exactly as your doctor has prescribed you. If you miss a dose, take it as soon as you remember. If you are not sure why, ask your doctor or pharmacist.
Pioglitazone may cause stomach upset, especially if you have stomach ulcers or bleeding problems. If you have problems sleeping or are more sensitive to light, tell your doctor right away.
Stade de France Pharmacy